546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

• Mark Middleton,
• Omid Hamid,
• Todd Bauer,
• Jessica Hassel,
• Friedegund Meier,
• Paolo Ascierto,
• John Kirkwood,
• Alexander Shoushtari,
• Marlana Orloff,
• April Salama,
• Paul Lorigan,
• Jeff Evans,
• Chris Holland,
• Shaad Abdullah,
• Cornelia Mauch,
• Ramakrishna Edukulla,
• Renee Mundy

Affiliations

Mark Middleton

Aff12 grid.451056.30000000121163923National Institute for Health Research Biomedical Research Centre London UK

Omid Hamid

Cedars-Sinai Medical Center Angeles Clinic and Research Institute, Santa Monica, California, USA

Todd Bauer

Aff106 grid.240145.60000000122914776University of Texas MD Anderson Cancer Center Houston TX USA

Jessica Hassel

Aff3 grid.5253.10000000103284908Heidelberg University Hospital Heidelberg Germany

Friedegund Meier

Department of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany

Paolo Ascierto

6Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy

John Kirkwood

16University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Alexander Shoushtari

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA

Marlana Orloff

2Thomas Jefferson University (Sarah Cannon), Philadelphia, PA, USA

April Salama

1Duke University, DURHAM, NC, USA

Paul Lorigan

Medical Oncology-Melanoma, The Christie Hospital NHS Trust, Manchester, UK

Jeff Evans

5Beatson Oncology Centre, Glasgow, UK

Chris Holland

16Immunocore, Rockville, USA

Shaad Abdullah

16Immunocore, Rockville, USA

Cornelia Mauch

10University Hospital Cologne, Cologne, Germany

Ramakrishna Edukulla

13Immunocore, Rockville, USA

Renee Mundy

13Immunocore, Rockville, USA